NextPlat's PharmcoRx Deploys Artificial Intelligence-Powered Prescription Processing Technology Supporting Expanded Nationwide Fulfillment Efforts

NextPlat (NASDAQ: NXPL) said its PharmcoRx subsidiary has deployed AI-powered prescription in-take and processing technology into its pharmacy management system effective April 16, 2026.

Rhea-AI Summary

NextPlat (NASDAQ: NXPL) said its PharmcoRx subsidiary has deployed AI-powered prescription in-take and processing technology into its pharmacy management system effective April 16, 2026. The tools automate data entry, faxing and refill management, create HIPAA-compliant digital workflows and support scaled fulfillment for new contracted clients.

Argus Apr 16 session

+4.39% close to close Open Argus

Details

News Market Reaction – NXPL

In the Apr 16 session, NXPL gained 4.39%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights NextPlat’s continued push to embed AI into its healthcare operations, e...

Analysis

This announcement highlights NextPlat’s continued push to embed AI into its healthcare operations, extending earlier ClearMetrX 4.0 and IoT initiatives into PharmcoRx prescription intake and fulfillment. The goal is to automate data entry, faxing, and refill management in fully HIPAA-compliant digital workflows and support nationwide growth. Against a backdrop of prior AI news that historically met with muted-to-negative price reactions, investors may watch for concrete evidence of efficiency gains, margin impact, and any use of the $300,000,000 shelf registration.

Previous AI Reports

2 past events · Latest: Dec 16

Same Type 2 events

1. Dec 16

   AI IoT expansion

   24h Move

   -2.4%

   GTC added 5G and AI-powered IoT solutions via Telit Cinterion deal.

2. Sep 23

   AI platform launch

   24h Move

   -11.6%

   Announced AI-enhanced ClearMetrX 4.0 healthcare analytics software rollout.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

artificial intelligence, ai-powered, pharmacy management system, hipaa, +2 more

6 terms

artificial intelligence technical

"state-of-the-art artificial intelligence (AI)-powered prescription in-take and processing"

Artificial intelligence is the ability of computers and machines to perform tasks that typically require human thinking, such as understanding language, recognizing patterns, or making decisions. For investors, it matters because AI can enhance efficiency, uncover new insights, and enable smarter strategies, potentially impacting the value and performance of companies that develop or utilize this technology.

ai-powered technical

"AI-powered prescription in-take and processing technology into its pharmacy management system"

"AI-powered" describes technology that uses artificial intelligence to perform tasks, make decisions, or analyze information automatically. It’s similar to having a highly skilled assistant that can learn from data, recognize patterns, and improve over time, helping to make processes faster and more accurate. For investors, this means better insights and more efficient operations, potentially leading to smarter investment choices.

pharmacy management system technical

"processing technology into its pharmacy management system"

A pharmacy management system is software that handles a pharmacy’s everyday tasks—prescriptions, inventory, billing, and patient records—like a digital control center that keeps pills, paperwork and payments organized. Investors care because the system affects a pharmacy’s efficiency, regulatory compliance and margins: better software can cut errors, speed service, reduce waste and enable growth, which can directly influence revenue and risk profiles.

hipaa regulatory

"creating fully-HIPAA compliant digital workflows"

A U.S. law that sets rules for keeping individuals’ health information private and secure, and for how that information can be shared. Think of it as a mandatory lock-and-key system for medical records that hospitals, insurers, and tech vendors must use. Investors care because failing to follow these rules can lead to big fines, costly remediation, loss of business access to patient data, and reputational damage that can hurt a company’s finances and growth prospects.

digital workflows technical

"creating fully-HIPAA compliant digital workflows"

Digital workflows are sequences of business tasks and approvals carried out and coordinated by software instead of paper, email chains, or manual handoffs. For investors, they matter because they can speed up operations, cut errors and costs, improve regulatory compliance and scaling, and make results more predictable—think of them as a digital assembly line or GPS that routes work faster and with fewer detours.

beta testing technical

"ClearMetrX 4.0 has now been deployed internally and is currently undergoing beta testing"

Beta testing is the stage when a nearly finished product is given to a group of real users outside the company so they can try it in everyday conditions and report problems or suggestions. For investors, a beta test is a practical check on whether a product works, whether users like it, and how quickly it can scale — like a dress rehearsal that reveals whether the show is ready for a paying audience and helps estimate future sales and risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

AI Technology to Automate Prescription In-Take, Improve Processing Accuracy and Reduce Costs as Fulfillment Volume Grows

HALLANDALE BEACH, Fla., April 16, 2026 /PRNewswire/ -- NextPlat Corp (NASDAQ: NXPL, NXPLW) ("NextPlat" or the "Company"), a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide, today announced that its PharmcoRx subsidiary has deployed state-of-the-art artificial intelligence (AI)-powered prescription in-take and processing technology into its pharmacy management system. This AI technology will support PharmcoRx as it seeks to improve the efficiency of its medication fulfillment processes as it expands the scale and scope of its offerings.

To provide improved prescription management and fulfilment services to customers while scaling to meet the anticipated growth in new contracted clients, the AI-powered software tools enable the rapid automation of previously manual processes including pharmacy data entry, faxing and refill management, creating fully-HIPAA compliant digital workflows. The AI software is being provided by an established pharmacy technology software vendor with a large installed base of clients in the U.S. and Canada and is undergoing capability enhancements led by PharmcoRx's internal digital transformation team. The enhanced AI software is expected to drive significant efficiency gains and cost reductions across the Company's pharmacy operations.

Birute Norkute, Vice President of Healthcare Operations at NextPlat, said, "At PharmcoRx, we continue to embrace the adoption of modern technology across our pharmacy operations because it can positively impact critical workflows, greatly improve efficiency, accuracy and reduce costs. As we now seek to rapidly expand our services and introduce new, high-value offerings, we believe the adoption of AI into our prescription processing workflows will enable us to more effectively scale our business while delivering greater value to our customers and patients."

The adoption of AI technology has been an important part of NextPlat's ongoing efforts to improve internal operational efficiencies and has been integrated into its recently upgraded ClearMetrX 4.0, the Company's next generation, proprietary healthcare data analytics and reporting software platform. ClearMetrX 4.0 has now been deployed internally and is currently undergoing beta testing by current clients.

For more information about NextPlat, please visit www.NextPlat.com and connect with us on Facebook, LinkedIn and X.

About NextPlat Corp
NextPlat is a global consumer products and services company providing healthcare and technology solutions through e-commerce and retail channels worldwide. Through acquisitions, joint ventures, and collaborations, the Company seeks to provide access to high quality healthcare and pharmacy services and assist businesses in selling their goods online, domestically, and internationally, allowing them to optimize their e-commerce presence and revenue. Through its subsidiaries, NextPlat provides pharmacy and healthcare data management services and prescription fulfilment services in the United States and operates an e-commerce division offering voice, data, tracking, and IoT products and services worldwide.

Forward-Looking Statements
Certain statements in this release constitute forward-looking statements. These statements include the capabilities and success of the Company's business and any of its products, services or solutions. The words "believe," "forecast," "project," "intend," "expect," "plan," "should," "would," and similar expressions and all statements, which are not historical facts, are intended to identify forward-looking statements. These forward-looking statements involve and are subject to known and unknown risks, uncertainties and other factors, including the Company's ability to successfully deploy artificial intelligence tools in its pharmacy operation, improve efficiencies and reduce costs, and expand as intended, any of which could cause the Company to not achieve some or all of its goals or the Company's previously reported actual results, performance (finance or operating), including those expressed or implied by such forward-looking statements. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (the "SEC"), copies of which may be obtained from the SEC's website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release.

Media and Investor Contact for NextPlat Corp:

Michael Glickman
MWGCO, Inc.
917-397-2272
mike@mwgco.net

View original content to download multimedia:https://www.prnewswire.com/news-releases/nextplats-pharmcorx-deploys-artificial-intelligence-powered-prescription-processing-technology-supporting-expanded-nationwide-fulfillment-efforts-302744247.html

SOURCE NextPlat Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did NextPlat (NXPL) announce about PharmcoRx on April 16, 2026?

PharmcoRx deployed AI-powered prescription in-take and processing technology to its pharmacy system. According to the company, the deployment automates manual tasks like data entry, faxing and refill management while enabling HIPAA-compliant digital workflows to support expanded fulfillment.

How will the new AI tools affect PharmcoRx prescription processing for NXPL?

The AI tools will automate manual workflows and improve processing accuracy and speed. According to the company, automation targets pharmacy data entry, faxing and refill management to reduce costs and scale fulfillment for growing contracted client volume.

Who provides the AI software used by PharmcoRx and how is it being enhanced?

An established pharmacy technology vendor with a large U.S. and Canada installed base supplies the AI software. According to the company, PharmcoRx's internal digital transformation team is leading capability enhancements and integrations.

Does NextPlat say the AI deployment is HIPAA compliant for pharmacy workflows?

Yes, the company states the AI-powered workflows are fully HIPAA compliant for prescription management. According to the company, compliance is built into the automated digital workflows covering data entry, faxing and refill handling.

How does the AI deployment relate to NextPlat's ClearMetrX 4.0 platform?

NextPlat integrated AI adoption into its upgraded ClearMetrX 4.0 analytics and reporting platform, now deployed internally. According to the company, ClearMetrX 4.0 is undergoing client beta testing alongside PharmcoRx's operational AI enhancements.